PL3568205T3 - Leczenie komórek nowotworowych z nadekspresją receptorów somatostatyny z użyciem pochodnych okreotydu chelatowanych z radioizotopami - Google Patents
Leczenie komórek nowotworowych z nadekspresją receptorów somatostatyny z użyciem pochodnych okreotydu chelatowanych z radioizotopamiInfo
- Publication number
- PL3568205T3 PL3568205T3 PL18703122.4T PL18703122T PL3568205T3 PL 3568205 T3 PL3568205 T3 PL 3568205T3 PL 18703122 T PL18703122 T PL 18703122T PL 3568205 T3 PL3568205 T3 PL 3568205T3
- Authority
- PL
- Poland
- Prior art keywords
- ocreotide
- chelated
- radioisotopes
- derivatives
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 108050001286 Somatostatin Receptor Proteins 0.000 title 1
- 102000011096 Somatostatin receptor Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762445541P | 2017-01-12 | 2017-01-12 | |
| PCT/US2018/013640 WO2018132751A1 (en) | 2017-01-12 | 2018-01-12 | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3568205T3 true PL3568205T3 (pl) | 2024-03-18 |
Family
ID=61157311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18703122.4T PL3568205T3 (pl) | 2017-01-12 | 2018-01-12 | Leczenie komórek nowotworowych z nadekspresją receptorów somatostatyny z użyciem pochodnych okreotydu chelatowanych z radioizotopami |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11541133B2 (pl) |
| EP (1) | EP3568205B1 (pl) |
| JP (1) | JP7084417B2 (pl) |
| KR (1) | KR102296752B1 (pl) |
| CN (1) | CN110678227B (pl) |
| AU (1) | AU2018207190B2 (pl) |
| CA (1) | CA3050094C (pl) |
| DK (1) | DK3568205T3 (pl) |
| ES (1) | ES2960030T3 (pl) |
| FI (1) | FI3568205T3 (pl) |
| HR (1) | HRP20231458T1 (pl) |
| HU (1) | HUE063981T2 (pl) |
| IL (1) | IL268012B (pl) |
| LT (1) | LT3568205T (pl) |
| PL (1) | PL3568205T3 (pl) |
| PT (1) | PT3568205T (pl) |
| RS (1) | RS64815B1 (pl) |
| SI (1) | SI3568205T1 (pl) |
| SM (1) | SMT202300398T1 (pl) |
| WO (1) | WO2018132751A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019240884A2 (en) * | 2018-04-27 | 2019-12-19 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| CA3166142A1 (en) * | 2020-01-29 | 2021-08-05 | Dongyoul Lee | Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers |
| US20230097381A1 (en) * | 2020-04-24 | 2023-03-30 | Radiomedix, Inc. | Composition, kit and method for diagnosis and treatment of prostate cancer |
| EP3973999A1 (en) * | 2020-09-28 | 2022-03-30 | Orano Med | Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof |
| WO2022081791A1 (en) * | 2020-10-14 | 2022-04-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Processes for synthesis of alpha-emitting radiopharmaceuticals |
| EP4029523A1 (en) * | 2021-01-19 | 2022-07-20 | Orano Med | Psma-targeting conjugate and uses thereof |
| NL2028075B1 (en) * | 2021-04-26 | 2022-11-03 | Alphathera Ag | Targeting system for cancer comprising a radioisotope |
| CN113277989B (zh) * | 2021-04-27 | 2022-05-31 | 中南大学湘雅医院 | 一种68Ga标记的分子探针、制备方法及其应用 |
| CN117377495A (zh) * | 2021-06-09 | 2024-01-09 | 克林提克斯医药股份有限公司 | 非肽靶向治疗剂及其用途 |
| US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
| EP4282439A1 (en) | 2022-05-23 | 2023-11-29 | Erasmus University Rotterdam Medical Center | Radioisotope labeled sstr2-agonists with linkers |
| NL2033489B1 (en) | 2022-11-09 | 2024-05-28 | Coretag Ip B V | Targeting system for cancer treatment |
| WO2024245421A1 (en) * | 2023-05-31 | 2024-12-05 | Full-Life Technologies Hk Limited | Radioligands for targeting cell surface receptors and uses thereof |
| CN117224713A (zh) * | 2023-06-28 | 2023-12-15 | 北京先通国际医药科技股份有限公司 | 212Pb-DOTATATE在制备用于治疗生长抑素受体阳性的胃肠胰腺神经内分泌瘤的药物中的用途 |
| TW202540073A (zh) * | 2023-11-30 | 2025-10-16 | 大陸商輻聯科技香港有限公司 | 靶向ｓｓｔｒ受體的放射性化合物及其用途 |
| WO2025163082A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2025171492A1 (en) | 2024-02-14 | 2025-08-21 | Alpha-9 Oncology Inc. | Stable radiopharmaceutical compositions and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004017D0 (en) | 1990-02-22 | 1990-04-18 | Krenning Eric P | Improvements in or relating to organic compounds |
| US6017512A (en) * | 1992-06-23 | 2000-01-25 | Diatide, Inc. | Radiolabeled peptides |
| GB9417873D0 (en) | 1994-09-06 | 1994-10-26 | Sandoz Ltd | Organic compounds |
| US5830431A (en) | 1995-06-07 | 1998-11-03 | Mallinckrodt Medical, Inc. | Radiolabeled peptide compositions for site-specific targeting |
| MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| US7361346B1 (en) | 1996-05-15 | 2008-04-22 | Altarex Corp. | Therapeutic compositions that produce an immune response |
| US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
| US6866837B2 (en) | 1998-06-05 | 2005-03-15 | Mallinckrodt Inc. | Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors |
| US6926883B1 (en) | 1999-06-29 | 2005-08-09 | Mallinckrodt Inc | Group (VII) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them |
| US6358491B1 (en) | 1999-08-27 | 2002-03-19 | Berlex Laboratories, Inc. | Somatostatin analogs |
| WO2001081426A2 (en) | 2000-04-26 | 2001-11-01 | Biosynthema Inc. | Rgd (arg-gly-asp) coupled to (neuro)peptides |
| AU2002211232B2 (en) | 2000-09-15 | 2006-10-19 | Sloan Kettering Institute For Cancer Research | Targeted alpha particle therapy using actinium-225 conjugates |
| JP5398945B2 (ja) | 2001-04-23 | 2014-01-29 | マリンクロッド エルエルシー | ＴｃおよびＲｅ標識放射活性グリコシル化オクトレオチド誘導体 |
| EP1283216A1 (en) | 2001-08-10 | 2003-02-12 | Mallinckrodt Inc. | Somatostatin analogues binding to all somatostatin receptor subtypes and their use |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US7122622B2 (en) * | 2002-04-16 | 2006-10-17 | Biosynthema Inc. | Peptide compounds having improved binding affinity to somatostatin receptors |
| JP2008513533A (ja) * | 2004-09-23 | 2008-05-01 | ゲルベ | Ｃｅｓｔイメージング用の造影剤封入システム |
| US20070025910A1 (en) | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
| US8097237B2 (en) | 2005-08-23 | 2012-01-17 | Stc.Unm | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma |
| EP1988925A2 (en) | 2006-02-24 | 2008-11-12 | Mallinckrodt, Inc. | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates |
| CN101400661A (zh) | 2006-03-14 | 2009-04-01 | 马林克罗特公司 | 四氮杂大环衍生物的金属络合物 |
| US20160045626A1 (en) * | 2007-01-11 | 2016-02-18 | Immunomedics, Inc. | Methods and Compositions for Improved Labeling of Targeting Peptides |
| MX340566B (es) | 2007-03-27 | 2016-07-14 | Radiomedix Inc | Composiciones para formacion de imagen objetivo y terapia. |
| US20100316566A1 (en) | 2008-02-27 | 2010-12-16 | Radiomedix Inc. | Radiolabeled hedgehog derivatives for imaging and therapy |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| WO2009151646A2 (en) | 2008-06-13 | 2009-12-17 | Stc.Unm | Non-invasive diagnostic agents and methods of diagnosing infectious disease |
| US8858916B2 (en) | 2008-09-30 | 2014-10-14 | Mallinckrodt Llc | Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent |
| US9603954B2 (en) | 2009-07-22 | 2017-03-28 | Actinium Pharmaceuticals Inc. | Methods for generating radioimmunoconjugates |
| US8986651B2 (en) | 2009-11-30 | 2015-03-24 | Stc.Unm | Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
| US20120052008A1 (en) | 2010-08-25 | 2012-03-01 | Yuri Mackeyev | Nanostructures comprising radioisotopes and/or metals |
| US9180214B1 (en) | 2011-04-22 | 2015-11-10 | Stc.Unm | Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer |
| PL2721045T3 (pl) | 2011-06-20 | 2017-11-30 | Radiomedix Inc. | Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych |
| EP2750717B1 (en) * | 2011-08-31 | 2019-03-27 | Somscan ApS | Pet tracer for imaging of neuroendocrine tumors |
| KR20140103140A (ko) * | 2011-12-13 | 2014-08-25 | 노르딕 나노벡터 에이에스 | 치료용 키메릭 항-cd37 항체 hh1 |
| LT2900279T (lt) | 2012-09-25 | 2019-11-11 | Advanced Accelerator Applications Usa Inc | Grpr antagonistai, skirti grpr atžvilgiu teigiamo vėžio nustatymui, diagnozavimui ir gydymui |
| EP2920156B9 (en) | 2012-10-02 | 2017-04-19 | Guerbet | Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates |
| US20140147381A1 (en) * | 2012-11-29 | 2014-05-29 | Gregory David Espenan | 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment |
| CA2915708C (en) | 2013-06-18 | 2018-02-06 | Aminomedix Inc. | Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids |
| US20150157742A1 (en) | 2013-12-11 | 2015-06-11 | The European Atomic Energy Community (Euratom), Represented By The European Commission | SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225 |
| GB201417067D0 (en) * | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
| US10927132B2 (en) * | 2015-02-27 | 2021-02-23 | Rochester Institute Of Technology | Transmetalation methods for the synthesis of PET and SPECT imaging agents |
| US20180126013A1 (en) * | 2015-05-06 | 2018-05-10 | H.Lee Moffitt Cancer Center And Research Institute, Inc. | Radiotherapeutic and companion imaging agents to target mc1r |
| DK3111959T3 (en) * | 2015-07-03 | 2018-01-02 | Oncoinvent As | Radiopharmaceutical particles and suspensions |
| CN106084005B (zh) | 2016-06-15 | 2020-02-14 | 广州军区广州总医院 | 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用 |
| FR3069245B1 (fr) * | 2017-07-21 | 2019-07-26 | Guerbet | Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales |
| CA3166142A1 (en) * | 2020-01-29 | 2021-08-05 | Dongyoul Lee | Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers |
-
2018
- 2018-01-12 SI SI201831005T patent/SI3568205T1/sl unknown
- 2018-01-12 RS RS20231056A patent/RS64815B1/sr unknown
- 2018-01-12 PL PL18703122.4T patent/PL3568205T3/pl unknown
- 2018-01-12 WO PCT/US2018/013640 patent/WO2018132751A1/en not_active Ceased
- 2018-01-12 CA CA3050094A patent/CA3050094C/en active Active
- 2018-01-12 LT LTEPPCT/US2018/013640T patent/LT3568205T/lt unknown
- 2018-01-12 AU AU2018207190A patent/AU2018207190B2/en active Active
- 2018-01-12 CN CN201880016106.7A patent/CN110678227B/zh active Active
- 2018-01-12 SM SM20230398T patent/SMT202300398T1/it unknown
- 2018-01-12 HR HRP20231458TT patent/HRP20231458T1/hr unknown
- 2018-01-12 US US16/477,623 patent/US11541133B2/en active Active
- 2018-01-12 DK DK18703122.4T patent/DK3568205T3/da active
- 2018-01-12 EP EP18703122.4A patent/EP3568205B1/en active Active
- 2018-01-12 JP JP2019558997A patent/JP7084417B2/ja active Active
- 2018-01-12 PT PT187031224T patent/PT3568205T/pt unknown
- 2018-01-12 KR KR1020197023200A patent/KR102296752B1/ko active Active
- 2018-01-12 ES ES18703122T patent/ES2960030T3/es active Active
- 2018-01-12 HU HUE18703122A patent/HUE063981T2/hu unknown
- 2018-01-12 FI FIEP18703122.4T patent/FI3568205T3/fi active
-
2019
- 2019-07-11 IL IL268012A patent/IL268012B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3568205T (lt) | 2024-02-12 |
| FI3568205T3 (fi) | 2023-11-01 |
| AU2018207190B2 (en) | 2020-12-03 |
| US20190336623A1 (en) | 2019-11-07 |
| AU2018207190A1 (en) | 2019-08-29 |
| DK3568205T3 (da) | 2023-10-09 |
| IL268012B (en) | 2021-12-01 |
| HUE063981T2 (hu) | 2024-02-28 |
| US11541133B2 (en) | 2023-01-03 |
| KR102296752B1 (ko) | 2021-09-02 |
| HRP20231458T1 (hr) | 2024-05-10 |
| CN110678227B (zh) | 2023-03-21 |
| EP3568205A1 (en) | 2019-11-20 |
| JP7084417B2 (ja) | 2022-06-14 |
| CA3050094A1 (en) | 2018-07-19 |
| PT3568205T (pt) | 2023-10-26 |
| SMT202300398T1 (it) | 2024-01-10 |
| JP2020505445A (ja) | 2020-02-20 |
| SI3568205T1 (sl) | 2023-12-29 |
| EP3568205B1 (en) | 2023-08-16 |
| RS64815B1 (sr) | 2023-12-29 |
| IL268012A (en) | 2019-09-26 |
| ES2960030T3 (es) | 2024-02-29 |
| CA3050094C (en) | 2024-01-02 |
| WO2018132751A1 (en) | 2018-07-19 |
| CN110678227A (zh) | 2020-01-10 |
| KR20200016196A (ko) | 2020-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202300398T1 (it) | Trattamento di cellule cancerose sovraesprimenti recettori della somatostatina usando derivati di ocreotide chelati a radioisotopi | |
| ZA201907641B (en) | Treatment of cancer by manipulation of commensal microflora | |
| IL282655A (en) | Methods of treating developmental disorders using pipradrol | |
| IL263678B (en) | Compounds for use in the treatment of breast cancer +ar | |
| IL252935A0 (en) | Cyclic dinucleotides used to treat cancer among others | |
| IL245758A0 (en) | Estrogen receptor modulator for the treatment of estrogen receptor-positive locally advanced or metastatic breast cancer | |
| PL3473263T3 (pl) | Preparaty łączone do leczenia raka | |
| IL282701B2 (en) | Methods for the synthesis of a radionuclide complex | |
| IL285077A (en) | Compounds for the treatment of cancer | |
| SG10201913964QA (en) | Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors | |
| SG11201701051RA (en) | A method for prognosis of ovarian cancer, patient's stratification | |
| PT3302063T (pt) | Método para estimulação de sementes | |
| IL247436A0 (en) | Preparations and methods for treating tumors that overexpress her2/neu | |
| IL277235A (en) | Preparations containing octreotide for the treatment of acromegaly | |
| SG11201706544SA (en) | Breast shield | |
| IL266917A (en) | Methods for treating prolactin receptor-positive breast cancer | |
| SG11201803118WA (en) | Therapeutic agent for breast cancer | |
| IL259781A (en) | Uses of pyrimido-pyridazinones to treat cancer | |
| IL246540A0 (en) | Freezeald receptor antibodies for cancer treatment | |
| PL3296294T3 (pl) | Związek do leczenia lub zapobiegania nowotworowi piersi | |
| SI2809327T1 (sl) | Hidroksialkil škrob v kombinaciji s citostatiki za zdravljenje rakov z zmanjševanjem stopenj rasti tumorja | |
| ZA201606921B (en) | Use of xanthophylls for the treatment of cancers | |
| EP3121274A4 (en) | METHOD FOR PREDICTING RESPONSIVENESS TO CANCER TREATMENT USING p300-INHIBITING COMPOUND | |
| IL255167A0 (en) | Compounds for the treatment of cancer | |
| GB201704976D0 (en) | System to facilitate idea development |